Functional dyspepsia

References

1 Nyrén O, Lindberg G, Lindstrom E et al. Economic Costs of Functional Dyspepsia. Pharmacoconomics 1992; 1(5): 312–324.

2 Chiba N, Bernard L, O’Brien BJ et al. A Canadian physician survey of dyspepsia management. Can J Gastroenterol 1998; 12: 183–190.

3 Talley NJ, Colin-Jones D, Koch KL et al. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 145–160.

4 Talley NJ, Stanghellinin V, Heading RC, Koch KL, Malageleda JR, Tytgat GNJ. Functional gastroduodenal disorders. Gut 1999; 45(suppl. II): 37–42.

5 Irvine EJ, Whitehead WE, Chey WD et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006; 130(5): 1538–1551.

6 Vakil N, Veldhuyzen van Zanten S, Kahrilas P, Dent J, Jones R, the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101(8): 1900–1920.

7 Fischler B, Tack J, De Gucht V et al. Heterogeneity of symptom pattern, psychosocial factors, and pathophysiological mechanisms in severe functional dyspepsia. Gastroenterology 2003; 124(4): 903–910.

8 Tack J, Jones MP, Karamanolis G, Coulie B, Dubois D. Symptom pattern and pathophysiological correlates of weight loss in tertiary-referred functional dyspepsia. Neurogastroenterol Motil. 2009 30. (Epub ahead of print).

9 Veldhuyzen van Zanten SJ, Flook N, Chiba N et al. An evidence- based approach to the management of uninvestigated dyspepsia in the era of Helicobacter pylori. Canadian Dyspepsia Working Group. Can Med Assoc J 2000; 162(12 suppl.): S3–23.

10 Chiba N, Van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment – Helicobacter pylori positive (CADET- Hp) randomised controlled trial. BMJ 2002; 324: 1012–1016.

11 Moayyedi P, Feltbower R, Brown J et al. Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group. Lancet 2000; 355: 1665– 1669.

12 Wildner-Christensen M, Moller Hansen J, Schaffalitzky De Muckadell OB. Rates of dyspepsia one year after Helicobacter pylori screening and eradication in a Danish population. Gastroenterology 2003; 125: 372–379.

13 van Marrewijk CJ, Mujakovic S, Fransen GA et al. Effect and cost-effectiveness of step-up versus step-down treatment with antacids, H2-receptor antagonists, and proton pump inhibitors in patients with new onset dyspepsia (DIAMOND study): a primary-care-based randomised controlled trial. Lancet 2009; 373(9659): 215–225.

14 Thomson AB, Barkun AN, Armstrong D et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Empiric Treatment – Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003; 17: 1481–1491.

15 Veldhuyzen van Zanten S, Armstrong D, Chiba N et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled “ENTER” trial. Am J GE 2006; 101: 2096–2106.

16 Talley NJ, Vakil N, Lauritsen K et al.

Only gold members can continue reading. Log In or Register to continue